Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

By LabMedica International staff writers
Posted on 20 Aug 2025

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. More...

Current biomarkers such as PD-L1 expression or tumor mutational burden often fail to reliably predict success due to the complexity of immune responses. Invasive tumor biopsies are also impractical for frequent monitoring. To address this gap, researchers have now developed a blood-based tool that predicts treatment response with high accuracy.

In the study, researchers from Fudan University Shanghai Cancer Center (Shanghai, China), along with collaborators, analyzed plasma samples from 195 TNBC patients undergoing immunotherapy, using high-sensitivity assays to track 92 immune-related proteins before, during, and after treatment. They identified three key proteins—ARG1, NOS3, and CD28—and combined them with others to create the PIPscore, a predictive model with 85.8% accuracy.

The study, published in Cancer Biology & Medicine, revealed dramatic shifts in plasma protein levels after immunotherapy. Responders showed rises in immune-activating proteins like CXCL9 and IFN-γ, while patients with pathologic complete response (pCR) had higher ARG1 and CD28 but lower NOS3. The PIPscore stratified patients into high- and low-response groups with strong precision and predicted 12-month progression-free survival with 96% accuracy.

To validate these findings, the researchers integrated single-cell RNA sequencing to link plasma proteomic changes to the tumor microenvironment. Elevated NOS3 was associated with reduced CD8+ T-cell presence, suggesting immunosuppressive effects, while ARG1’s role in arginine metabolism may enhance T-cell activity. ELISA tests confirmed the reliability of the proteomic platform, further strengthening the clinical value of the PIPscore.

The PIPscore’s prognostic power offers oncologists a non-invasive method to guide treatment selection. By identifying ideal candidates for immunotherapy, the model could minimize unnecessary side effects and reduce treatment costs. Its ability to monitor patients in real time also supports dynamic treatment adjustments. Beyond TNBC, this approach may extend to other cancers where immunotherapy response remains highly variable.

“This study transforms how we approach TNBC immunotherapy. By translating complex plasma proteomics into a practical score, we've bridged the gap between research and clinical utility. The PIPscore not only predicts response but also opens doors to targeting metabolic pathways like arginine deprivation to overcome resistance. These findings underscore that systemic immunity, not just the tumor microenvironment, dictates treatment success,” said Dr. Yizhou Jiang, co-corresponding author of the study.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.